Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J KEATING

Showing results (681-690 of 1,115) with videos related to

Pageof 112
Sort By:
The American Surgeon|December 21, 2020
Outcomes in Delayed Drainage of HemothoraxJessica L Weaver, Elinore J Kaufman, Andrew J Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1985
Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemiaH M Kantarjian, L Vellekoop, K B McCredie, et al.
Leukemia & Lymphoma|August 3, 2002
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disordersApostolia M Tsimberidou, Susan M O'Brien, Jorge E Cortes, et al.
The Journal of Clinical Endocrinology and Metabolism|February 14, 2019
Metformin Triggers PYY Secretion in Human Gut MucosaEmily W Sun, Alyce M Martin, David A Wattchow, et al.
Cancer|July 13, 2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemiaStefan Faderl, Kanti Rai, John Gribben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1991
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemiaM J Keating, H Kantarjian, S O'Brien, et al.
Leukemia|October 27, 1997
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemiaS Sacchi, H M Kantarjian, S O'Brien, et al.
Plos One|June 7, 2019
Interactions of nuclear transport factors and surface-conjugated FG nucleoporins: Insights and limitationsRyo Hayama, Mirco Sorci, John J Keating Iv, et al.
Blood|November 1, 1991
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemiaH M Kantarjian, M Talpaz, K Dhingra, et al.
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Pageof 112

Showing results (681-690 of 1,115) with videos related to

Sort By:
Pageof 112
The American Surgeon|December 21, 2020
Outcomes in Delayed Drainage of HemothoraxJessica L Weaver, Elinore J Kaufman, Andrew J Young, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1985
Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemiaH M Kantarjian, L Vellekoop, K B McCredie, et al.
Leukemia & Lymphoma|August 3, 2002
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disordersApostolia M Tsimberidou, Susan M O'Brien, Jorge E Cortes, et al.
The Journal of Clinical Endocrinology and Metabolism|February 14, 2019
Metformin Triggers PYY Secretion in Human Gut MucosaEmily W Sun, Alyce M Martin, David A Wattchow, et al.
Cancer|July 13, 2006
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemiaStefan Faderl, Kanti Rai, John Gribben, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1991
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemiaM J Keating, H Kantarjian, S O'Brien, et al.
Leukemia|October 27, 1997
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemiaS Sacchi, H M Kantarjian, S O'Brien, et al.
Plos One|June 7, 2019
Interactions of nuclear transport factors and surface-conjugated FG nucleoporins: Insights and limitationsRyo Hayama, Mirco Sorci, John J Keating Iv, et al.
Blood|November 1, 1991
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemiaH M Kantarjian, M Talpaz, K Dhingra, et al.
British Journal of Clinical Pharmacology|May 18, 2007
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment responseD R Mould, A Baumann, J Kuhlmann, et al.
Pageof 112